Trio appointed to Babraham Bioscience Technologies board
Babraham Bioscience Technologies has appointed three new board members.
The organisation oversees the development and day-to-day management of Babraham Research Campus.
Prof Wolf Reik, the acting director of the Babraham Institute, will represent its trustees’ shareholder interests on the board, and replaces Clive Page, professor of pharmacology and director of the Sackler Institute of Pulmonary Pharmacology at King’s College London, who is stepping down after many years of service.
Prof Reik, who heads up the Institute’s epigenetics research programme, said the campus illustrates how “cutting edge fundamental science connects with cutting edge biotech development”.
He added: “As the campus continues to evolve my hope and expectation is that it will continue to attract an increasingly diverse set of new talent; leading to new career ideas and opportunities at the interface of fundamental bioscience and its translation.”
Meanwhile, Alexander Hewitson, head of operations at AstraZeneca, and Dr Clive Stanway, an independent cancer drug discovery and development advisor, most recently with Cancer Research UK, join the board as independent non-executive directors.
Alex said: “I am delighted to be joining the BBT Board at such an exciting time for both the Babraham Research Campus and the wider Cambridge life-science cluster.
“The Babraham Research Campus is at the forefront in supporting the UK’s bioscience enterprises and in delivering a supportive ecosystem across life science research; as such I look forward to helping shape its continued success.”
Clive added: “I’ve always found the Babraham Research Campus to be an inspirational setting for biomedical research and I’m therefore delighted to be joining the BBT board to help drive the next steps for this exciting community.”
Dr Andy Richards, chairman of the BBT board said the trio “bring particular knowledge, skills and capabilities that complement those of the existing board” and also thanks Prof Page for his “immense contribution”.
Sign up for our newsletter for the latest Cambridge science and business news direct to your inbox